Welcome to our dedicated page for Acurx Pharmaceuticals news (Ticker: ACXP), a resource for investors and traders seeking the latest updates and insights on Acurx Pharmaceuticals stock.
Acurx Pharmaceuticals, Inc. develops small-molecule antibiotics for difficult-to-treat bacterial infections through a Gram-positive selective spectrum approach targeting DNA polymerase IIIC. Its pipeline includes ibezapolstat for Clostridioides difficile infection and additional DNA pol IIIC inhibitor candidates directed at Gram-positive pathogens such as MRSA, VRE, drug-resistant Streptococcus pneumoniae and B. anthracis.
Recurring ACXP news covers antibiotic development updates, microbiome data, scientific conference presentations, intellectual property for DNA pol IIIC inhibitors, financial results, registered offerings, warrant activity and investor-presentation announcements.
Acurx Pharmaceuticals (NASDAQ: ACXP) will release its Q2 2021 financial results on August 17, 2021, at 8:30 a.m. ET. A conference call will be hosted by President David P. Luci and CFO Robert G. Shawah to discuss these results and provide a business update. The company is developing ibezapolstat, a novel oral antibiotic for C. difficile infection, which has received FDA designations as a Qualified Infectious Disease Product and Fast Track designation. Acurx plans to enroll in a Phase 2b efficacy study by the end of 2021.
Acurx Pharmaceuticals (NASDAQ: ACXP) filed a provisional patent for ibezapolstat, targeting Clostridioides difficile Infection (CDI) and aiming to improve gut microbiome health. Following a successful Phase 2a trial with a 100% clinical cure rate, Acurx will initiate a Phase 2b trial later this year. The company's approach focuses on dual-action therapy, potentially enhancing patient outcomes and reducing recurrence rates. The announcement reflects Acurx's commitment to protecting its antimicrobial technologies.
Acurx Pharmaceuticals (Nasdaq ACXP) announced promising results for ibezapolstat in preventing Clostridioides difficile Infection (CDI) recurrence during the World Microbe Forum 2021. Utilizing specimens from a Phase 1 trial, analysis indicates ibezapolstat may lower CDI recurrence risk compared to vancomycin. Dr. Kevin Garey highlighted its unique microbiome impact, suggesting a restorative effect. Acurx plans to further validate these findings in a Phase 2b trial. CDI remains a serious health issue, with approximately 600,000 infections annually in the U.S.
Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) has successfully closed its initial public offering, selling 2,875,000 shares at $6.00 each, including an option for underwriters to purchase 375,000 additional shares. The offering generated approximately $14.8 million in net proceeds for the company. The SEC declared the registration statement effective on June 24, 2021. Acurx focuses on developing new antibiotics targeting difficult-to-treat bacterial infections.
Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) announced the pricing of an underwritten initial public offering of 2,500,000 shares at $6.00 per share, aiming to raise approximately $15 million. The offering includes a 45-day option for underwriters to purchase an additional 375,000 shares. The proceeds will fund a Phase 2b clinical trial for ibezapolstat and pre-clinical development of ACX-375C, alongside general corporate purposes. Trading is set to begin on June 25, 2021, with the closing expected on June 29, 2021, subject to customary conditions.